Search research articles
Contact Us
Filters
Showing results (171-180 of 206) with videos related to
Page
of 21
Sort By:
Molecular Cancer Therapeutics
|
May 20, 2016
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab
Satoshi Okazaki, Fotios Loupakis, Sebastian Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2025
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306
Julian Walter Holch, Alexander J Ohnmacht, Sebastian Stintzing, et al.
Eclinicalmedicine
|
January 13, 2025
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial
Arndt Stahler, Meinolf Karthaus, Stefan Fruehauf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2023
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study
Sebastian Stintzing, Kathrin Heinrich, David Tougeron, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 18, 2022
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)
Greta Sommerhäuser, Annika Kurreck, Alexander Beck, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 19, 2020
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, et al.
British Journal of Cancer
|
August 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials
Alexej Ballhausen, Federica Morano, Arndt Stahler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2021
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
Dominik Paul Modest, Meinolf Karthaus, Stefan Fruehauf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2020
Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study)
Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2026
<SPAN style="font-weight: 400;">Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer</SPAN>
Julius Keyl, René Hosch, Fabian Hörst, et al.
Page
of 21
Search research articles
Search
Showing results (171-180 of 206) with videos related to
Sort By:
Page
of 21
Molecular Cancer Therapeutics
|
May 20, 2016
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab
Satoshi Okazaki, Fotios Loupakis, Sebastian Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 3, 2025
FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306
Julian Walter Holch, Alexander J Ohnmacht, Sebastian Stintzing, et al.
Eclinicalmedicine
|
January 13, 2025
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial
Arndt Stahler, Meinolf Karthaus, Stefan Fruehauf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 23, 2023
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of <i>BRAF</i><sup>V600E</sup>-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study
Sebastian Stintzing, Kathrin Heinrich, David Tougeron, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 18, 2022
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)
Greta Sommerhäuser, Annika Kurreck, Alexander Beck, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 19, 2020
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, et al.
British Journal of Cancer
|
August 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials
Alexej Ballhausen, Federica Morano, Arndt Stahler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2021
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
Dominik Paul Modest, Meinolf Karthaus, Stefan Fruehauf, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 5, 2020
Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study)
Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 5, 2026
<SPAN style="font-weight: 400;">Deep Learning-derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-Type Metastatic Colorectal Cancer</SPAN>
Julius Keyl, René Hosch, Fabian Hörst, et al.
Page
of 21